ESTRO GUIDE 2017

RADIOBIOLOGY PRE-MEETING COURSE Clinical application of biomarkers: How to discover, explore, and validate biomarkers for normal tissue toxicity and tumour response

FRIDAY 5 MAY 2017 Course directors: J. Alsner (DK) and M-C. Vozenin (CH)

Normal tissue • Genetic biomarkers: genomic DNA

COURSE AIM Enable participants to understand the scientific and clinical aspects associated with discovery, exploration, and validation of biomarkers for personalised/precision radiation oncology (PRO) and raise awareness of key challenges in this important field. LEARNINGOBJECTIVES • To comprehend the basic principles of prognostic and predictive biomarkers • To assess the relevance of biomarkers for normal tissue toxicity • To assess the relevance of biomarkers for tumour response • To propose strategies for validation of biomarkers • To propose strategies for implementing imaging and molecular biomarkers for PRO • To analyse legal and patent aspects for the clinical use of biomarkers. WHO SHOULD ATTEND? • Radiation oncologists, particularly those in the early stage of their career, who are keen to understand how biomarkers are important for PRO • Radiation biologists seeking information on how to maximise the clinical impact of their scientific discoveries • Medical physicists and RTTs looking for an overview and update of recent and ongoing developments in the field of biomarkers. CONTENT Prognostic and predictive biomarkers Tumour response • Genetic biomarkers: mutations andmRNA / miRNA profiles • Imaging biomarkers: PET / MR • Imaging biomarkers: radiomics • Circulating tumour cells and cell-free DNA / RNA.

• Genetic biomarkers: mitochondrial DNA • Proteomic / metabolomic biomarkers • Functional biomarkers. Validation • Design methodology for biomarker based radio- therapy trials • Clinical trial example (EORTC-1219): Randomised prospectivemulticenter study testing a radiosensitizer and a predictive biomarker.

ESTRO CONFERENCES

135